Kerecis is developing the MariGen™ Omega3 acellular dermal matrix technology for use in products to treat chronic wounds, for dura mater repair, breast reconstruction and abdominal wall reconstruction. Our patent pending acellular fish skin derived material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.
Kerecis was established as a medical device / biotech company in 2009 and completed its seed round late 2009. In 2011 the company closed its "A1" round, late 2012 round “A2” was closed and round "A3" was closed at the end of 2013 . The company is targeting the close of its "B" round spring 2014.
The company is actively seeking future licensing and distribution partners, while focusing on product development, intellectual property protection and clinical tests. Ideal potential technology licensees will have the ability to undertake market launch of these proprietary devices in markets around the world.